Investigation  ||| S:0 E:14 ||| NN
of  ||| S:14 E:17 ||| IN
the  ||| S:17 E:21 ||| DT
interplay  ||| S:21 E:31 ||| NN
between  ||| S:31 E:39 ||| IN
plasma  ||| S:39 E:46 ||| JJ
lipids  ||| S:46 E:53 ||| NN
and  ||| S:53 E:57 ||| CC
macrophage  ||| S:57 E:68 ||| JJ
polarization  ||| S:68 E:81 ||| NN
in  ||| S:81 E:84 ||| IN
small  ||| S:84 E:90 ||| JJ
oral  ||| S:90 E:95 ||| JJ
squamous  ||| S:95 E:104 ||| JJ
cell  ||| S:104 E:109 ||| NN
carcinomas  ||| S:109 E:120 ||| NN
with  ||| S:120 E:125 ||| IN
different  ||| S:125 E:135 ||| JJ
outcome ||| S:135 E:142 ||| NN
:  ||| S:142 E:144 ||| :
A  ||| S:144 E:146 ||| DT
pilot  ||| S:146 E:152 ||| NN
study  ||| S:152 E:158 ||| NN
of  ||| S:158 E:161 ||| IN
17  ||| S:161 E:164 ||| CD
cases  ||| S:164 E:170 ||| NNS
Growing  ||| S:170 E:178 ||| VBG
evidence  ||| S:178 E:187 ||| NN
suggests  ||| S:187 E:196 ||| VBZ
a  ||| S:196 E:198 ||| DT
correlation  ||| S:198 E:210 ||| NN
of  ||| S:210 E:213 ||| IN
alternative  ||| S:213 E:225 ||| JJ
polarization  ||| S:225 E:238 ||| NN
of  ||| S:238 E:241 ||| IN
macrophages  ||| S:241 E:253 ||| NNS
( ||| S:253 E:254 ||| -LRB-
M2 ||| S:254 E:256 ||| CD
)  ||| S:256 E:258 ||| -RRB-
with  ||| S:258 E:263 ||| IN
a  ||| S:263 E:265 ||| DT
bad  ||| S:265 E:269 ||| JJ
outcome  ||| S:269 E:277 ||| NN
of  ||| S:277 E:280 ||| IN
oral  ||| S:280 E:285 ||| JJ
cancer ||| S:285 E:291 ||| NN
.  ||| S:291 E:293 ||| .
Macrophage  ||| S:293 E:304 ||| JJ
polarization  ||| S:304 E:317 ||| NN
plays  ||| S:317 E:323 ||| VBZ
a  ||| S:323 E:325 ||| DT
significant  ||| S:325 E:337 ||| JJ
role  ||| S:337 E:342 ||| NN
in  ||| S:342 E:345 ||| IN
the  ||| S:345 E:349 ||| DT
progression  ||| S:349 E:361 ||| NN
of  ||| S:361 E:364 ||| IN
hyperlipidemia  ||| S:364 E:379 ||| NN
and  ||| S:379 E:383 ||| CC
atherosclerosis ||| S:383 E:398 ||| NN
,  ||| S:398 E:400 ||| ,
being  ||| S:400 E:406 ||| VBG
influenced  ||| S:406 E:417 ||| VBN
from  ||| S:417 E:422 ||| IN
plasma  ||| S:422 E:429 ||| JJ
cholesterol ||| S:429 E:440 ||| NN
.  ||| S:440 E:442 ||| .
On  ||| S:442 E:445 ||| IN
the  ||| S:445 E:449 ||| DT
other  ||| S:449 E:455 ||| JJ
hand  ||| S:455 E:460 ||| NN
plasma  ||| S:460 E:467 ||| NN
lipids  ||| S:467 E:474 ||| NNS
have  ||| S:474 E:479 ||| VBP
been  ||| S:479 E:484 ||| VBN
studied  ||| S:484 E:492 ||| VBN
epidemiologically  ||| S:492 E:510 ||| VBN
as  ||| S:510 E:513 ||| IN
risk  ||| S:513 E:518 ||| NN
factors  ||| S:518 E:526 ||| NNS
in  ||| S:526 E:529 ||| IN
carcinogenesis ||| S:529 E:543 ||| NN
.  ||| S:543 E:545 ||| .
Goal  ||| S:545 E:550 ||| NN
of  ||| S:550 E:553 ||| IN
our  ||| S:553 E:557 ||| PRP$
pilot  ||| S:557 E:563 ||| NN
study  ||| S:563 E:569 ||| NN
was  ||| S:569 E:573 ||| VBD
the  ||| S:573 E:577 ||| DT
investigation  ||| S:577 E:591 ||| NN
of  ||| S:591 E:594 ||| IN
a  ||| S:594 E:596 ||| DT
possible  ||| S:596 E:605 ||| JJ
association  ||| S:605 E:617 ||| NN
of  ||| S:617 E:620 ||| IN
plasma  ||| S:620 E:627 ||| JJ
lipids  ||| S:627 E:634 ||| NN
with  ||| S:634 E:639 ||| IN
tumor  ||| S:639 E:645 ||| NN
outcome  ||| S:645 E:653 ||| NN
through  ||| S:653 E:661 ||| IN
their  ||| S:661 E:667 ||| PRP$
potential  ||| S:667 E:677 ||| JJ
influence  ||| S:677 E:687 ||| NN
on  ||| S:687 E:690 ||| IN
macrophage  ||| S:690 E:701 ||| CD
polarization.  ||| S:701 E:715 ||| CD
17  ||| S:715 E:718 ||| CD
patients  ||| S:718 E:727 ||| NNS
with  ||| S:727 E:732 ||| IN
small  ||| S:732 E:738 ||| JJ
pN0  ||| S:738 E:742 ||| NNP
OSCC  ||| S:742 E:747 ||| NNP
with  ||| S:747 E:752 ||| IN
different  ||| S:752 E:762 ||| JJ
clinical  ||| S:762 E:771 ||| JJ
outcome ||| S:771 E:778 ||| NN
,  ||| S:778 E:780 ||| ,
treated  ||| S:780 E:788 ||| VBN
operatively  ||| S:788 E:800 ||| VBN
without  ||| S:800 E:808 ||| IN
postoperative  ||| S:808 E:822 ||| JJ
R ||| S:822 E:823 ||| NN
( ||| S:823 E:824 ||| -LRB-
C ||| S:824 E:825 ||| NNP
) ||| S:825 E:826 ||| -RRB-
T  ||| S:826 E:828 ||| NN
constituted  ||| S:828 E:840 ||| VBD
our  ||| S:840 E:844 ||| PRP$
patient  ||| S:844 E:852 ||| JJ
collective ||| S:852 E:862 ||| JJ
.  ||| S:862 E:864 ||| .
Plasma  ||| S:864 E:871 ||| JJ
lipids  ||| S:871 E:878 ||| NNS
( ||| S:878 E:879 ||| -LRB-
total  ||| S:879 E:885 ||| JJ
cholesterol  ||| S:885 E:897 ||| NN
and  ||| S:897 E:901 ||| CC
triglycerides ||| S:901 E:914 ||| CD
)  ||| S:914 E:916 ||| -RRB-
were  ||| S:916 E:921 ||| VBD
studied  ||| S:921 E:929 ||| VBN
in  ||| S:929 E:932 ||| IN
relation  ||| S:932 E:941 ||| NN
to  ||| S:941 E:944 ||| TO
macrophage  ||| S:944 E:955 ||| VB
polarization  ||| S:955 E:968 ||| NNS
( ||| S:968 E:969 ||| -LRB-
determined  ||| S:969 E:980 ||| VBN
through  ||| S:980 E:988 ||| IN
the  ||| S:988 E:992 ||| DT
expression  ||| S:992 E:1003 ||| NN
of  ||| S:1003 E:1006 ||| IN
CD68 ||| S:1006 E:1010 ||| NNP
,  ||| S:1010 E:1012 ||| ,
CD11c ||| S:1012 E:1017 ||| NNP
,  ||| S:1017 E:1019 ||| ,
CD163  ||| S:1019 E:1025 ||| NNP
and  ||| S:1025 E:1029 ||| CC
MRC1  ||| S:1029 E:1034 ||| CD
antibodies ||| S:1034 E:1044 ||| NNS
)  ||| S:1044 E:1046 ||| -RRB-
and  ||| S:1046 E:1050 ||| CC
tumor  ||| S:1050 E:1056 ||| NN
outcome ||| S:1056 E:1063 ||| NN
.  ||| S:1063 E:1065 ||| .
Patients  ||| S:1065 E:1074 ||| NNS
with  ||| S:1074 E:1079 ||| IN
pathological  ||| S:1079 E:1092 ||| JJ
chronic  ||| S:1092 E:1100 ||| JJ
course  ||| S:1100 E:1107 ||| NN
of  ||| S:1107 E:1110 ||| IN
either  ||| S:1110 E:1117 ||| DT
plasma  ||| S:1117 E:1124 ||| JJ
cholesterol  ||| S:1124 E:1136 ||| NN
or  ||| S:1136 E:1139 ||| CC
triglycerides  ||| S:1139 E:1153 ||| NNS
demonstrated  ||| S:1153 E:1166 ||| VBD
an  ||| S:1166 E:1169 ||| DT
increased  ||| S:1169 E:1179 ||| JJ
infiltration  ||| S:1179 E:1192 ||| NN
with  ||| S:1192 E:1197 ||| IN
alternatively  ||| S:1197 E:1211 ||| RB
polarized  ||| S:1211 E:1221 ||| JJ
macrophages  ||| S:1221 E:1233 ||| NN
in  ||| S:1233 E:1236 ||| IN
their  ||| S:1236 E:1242 ||| PRP$
specimens ||| S:1242 E:1251 ||| NNS
.  ||| S:1251 E:1253 ||| .
Patients  ||| S:1253 E:1262 ||| NNS
with  ||| S:1262 E:1267 ||| IN
pathological  ||| S:1267 E:1280 ||| JJ
chronic  ||| S:1280 E:1288 ||| JJ
course  ||| S:1288 E:1295 ||| NN
of  ||| S:1295 E:1298 ||| IN
plasma  ||| S:1298 E:1305 ||| JJ
cholesterol  ||| S:1305 E:1317 ||| NN
showed  ||| S:1317 E:1324 ||| VBD
moreover  ||| S:1324 E:1333 ||| RB
a  ||| S:1333 E:1335 ||| DT
bad  ||| S:1335 E:1339 ||| JJ
tumor  ||| S:1339 E:1345 ||| NN
outcome ||| S:1345 E:1352 ||| NN
.  ||| S:1352 E:1354 ||| .
A  ||| S:1354 E:1356 ||| DT
role  ||| S:1356 E:1361 ||| NN
of  ||| S:1361 E:1364 ||| IN
plasma  ||| S:1364 E:1371 ||| JJ
lipids  ||| S:1371 E:1378 ||| NN
in  ||| S:1378 E:1381 ||| IN
the  ||| S:1381 E:1385 ||| DT
tumor  ||| S:1385 E:1391 ||| NN
outcome  ||| S:1391 E:1399 ||| NN
via  ||| S:1399 E:1403 ||| IN
alternative  ||| S:1403 E:1415 ||| JJ
macrophage  ||| S:1415 E:1426 ||| JJ
polarization  ||| S:1426 E:1439 ||| NN
could  ||| S:1439 E:1445 ||| MD
be  ||| S:1445 E:1448 ||| VB
assumed ||| S:1448 E:1455 ||| VBN
.  ||| S:1455 E:1457 ||| .
A  ||| S:1457 E:1459 ||| DT
larger  ||| S:1459 E:1466 ||| JJR
prospective  ||| S:1466 E:1478 ||| JJ
study  ||| S:1478 E:1484 ||| NN
is  ||| S:1484 E:1487 ||| VBZ
needed  ||| S:1487 E:1494 ||| VBN
to  ||| S:1494 E:1497 ||| TO
confirm  ||| S:1497 E:1505 ||| VB
our  ||| S:1505 E:1509 ||| PRP$
preliminary  ||| S:1509 E:1521 ||| JJ
results ||| S:1521 E:1528 ||| NNS
.  ||| S:1528 E:1530 ||| .
